REFERENCES
1. Deng, C.; Hu, Y.; Zhu, D.; et al. Single-cell RNA-seq reveals fibroblast heterogeneity and increased mesenchymal fibroblasts in human fibrotic skin diseases. Nat. Commun. 2021, 12, 24110.
2. Zhao, Y.; Wei, Q.; Zeng, R.; Wang, Y.; Yang, Y.; Wang, Y. Natural killer cell dysfunction drives keloid pathogenesis. Cell. Rep. 2026, 45, 117129.
3. Nagar, H.; Kim, S.; Lee, I.; et al. Downregulation of CR6-interacting factor 1 suppresses keloid fibroblast growth via the TGF-β/Smad signaling pathway. Sci. Rep. 2021, 11, 79785.
4. Chao, H.; Zheng, L.; Hsu, P.; et al. IL-13RA2 downregulation in fibroblasts promotes keloid fibrosis via JAK/STAT6 activation. JCI. Insight. 2023, 8, e157091.
5. Sun, Y.; Chen, Z.; Zhang, M.; et al. FOSL1-mediated super-enhancer facilitates pathological scarring. Cell. Rep. 2026, 45, 117667.
6. Cheng, X.; Gao, Z.; Shan, S.; et al. Single cell transcriptomics reveals the cellular heterogeneity of keloids and the mechanism of their aggressiveness. Commun. Biol. 2024, 7, 7311.
7. Zhang, Y.; Bao, Y.; Li, Z.; Jin, Z. A novel nude mice model for studying the pathogenesis of keloid. J. Cosmet. Dermatol. 2025, 24, e70284.
8. Ancuța, D.; Văduva, M.; Coman, C.; Caraș, I. Recent advances in animal models for pathological scar research: a comprehensive review of experimental approaches and translational relevance. Animal. Model. Exp. Med. 2026, 9, 59-71.
9. Abergel, R. P.; Pizzurro, D.; Meeker, C. A.; et al. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. J. Invest. Dermatol. 1985, 84, 384-90.
10. Lim, I. J.; Phan, T.; Song, C.; Tan, W. T. L.; Longaker, M. T. Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast. Reconstr. Surg. 2001, 107, 797-808.
11. Limandjaja, G. C.; van den Broek, L. J.; Breetveld, M.; et al. Characterization of in vitro reconstructed human normotrophic, hypertrophic, and keloid scar models. Tissue. Eng. Part. C. Methods. 2018, 24, 242-53.
12. Ahn, M.; Cho, W.; Park, W.; et al. 3D biofabrication of diseased human skin models in vitro. Biomater. Res. 2023, 27, 80.
13. Choi, Y.; Jang, H.; Shim, J.; et al. 3D keloid spheroid model: development and application for personalized drug response prediction. Commun. Biol. 2024, 7, 7194.
14. Dirand, Z.; Tissot, M.; Chatelain, B.; Viennet, C.; Rolin, G. Is spheroid a relevant model to address fibrogenesis in keloid research? Biomedicines 2023, 11, 2350.
15. Ingber, D. E. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat. Rev. Genet. 2022, 23, 467-91.
16. Leung, C. M.; de Haan, P.; Ronaldson-Bouchard, K.; et al. A guide to the organ-on-a-chip. Nat. Rev. Methods. Primers. 2022, 2, 33.
17. Sutterby, E.; Thurgood, P.; Baratchi, S.; Khoshmanesh, K.; Pirogova, E. Microfluidic skin‐on‐a‐chip models: toward biomimetic artificial skin. Small 2020, 16, 2002515.
18. Lee, T.; Kyung, S. Y.; Kwon, M.; Park, B.; Ko, J. Innovations in skin microphysiological systems for nonclinical testing and FDA modernization. Microsyst. Nanoeng. 2026, 12, 1149.
19. Kim, K.; Kim, H.; Sung, G. Y. An interleukin-4 and interleukin-13 induced atopic dermatitis human skin equivalent model by a skin-on-a-chip. Int. J. Mol. Sci. 2022, 23, 2116.
20. Sun, S.; Jin, L.; Zheng, Y.; Zhu, J. Modeling human HSV infection via a vascularized immune-competent skin-on-chip platform. Nat. Commun. 2022, 13, 33114.
21. Streutker, E. M.; Devamoglu, U.; Vonk, M. C.; Verdurmen, W. P. R.; Le Gac, S. Fibrosis‐on‐chip: a guide to recapitulate the essential features of fibrotic disease. Adv. Healthc. Mater. 2024, 13, e2303991.
22. Abdo, D.; Zhao, Y.; Okhovatian, S.; et al. A dermis-on-a-chip model for compound screening. Mater. Today. Bio. 2025, 34, 102111.
23. Li, P.; Cui, F.; Chen, H.; et al. A microfluidic cell co-culture chip for the monitoring of interactions between macrophages and fibroblasts. Biosensors 2023, 13, 70.
24. Biglari, S.; Le, T. Y. L.; Tan, R. P.; et al. Simulating inflammation in a wound microenvironment using a dermal wound‐on‐a‐chip model. Adv. Healthc. Mater. 2019, 8, e1801307.
25. Matei, A. E.; Chen, C. W.; Kiesewetter, L.; et al. Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs. Ann. Rheum. Dis. 2019, 78, 1686-92.
26. Rimal, R.; Marquardt, Y.; Nevolianis, T.; et al. Dynamic flow enables long‐term maintenance of 3‐D vascularized human skin models. Appl. Mater. Today. 2021, 25, 101213.
27. Pappalardo, A.; Ornek, D.; Cerda, L. G.; et al. A mechanomimetic model of skin fibrosis. Lab. Chip. 2026, 26, 665-80.
28. Yue, K.; Trujillo-de Santiago, G.; Alvarez, M. M.; Tamayol, A.; Annabi, N.; Khademhosseini, A. Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels. Biomaterials 2015, 73, 254-71.
29. Zhang, J.; Chen, Z.; Zhang, Y.; et al. Construction of a high fidelity epidermis-on-a-chip for scalable in vitro irritation evaluation. Lab. Chip. 2021, 21, 3804-18.
30. Rittié, L.; Fisher, G. J. Isolation and culture of skin fibroblasts. Methods. Mol. Med. 2005, 117, 83-98.
31. Brietzke, A.; Guthoff, R. F.; Grabow, N.; Stahnke, T. Nintedanib suppresses expression of extracellular matrix proteins in TGF-β1-stimulated primary human fibroblasts of the Tenon. Curr. Dir. Biomed. Eng. 2021, 7, 367-70.
32. Nobari, S.; Najafi, R.; Mahdavinezhad, A.; jalali, A.; Amini, R.; Emran, T. B. The combination of zerumbone with 5-fluorouracil for sensitizing colorectal cancer-associated fibroblasts to treatment. Evid. Based. Complement. Alternat. Med. 2022, 2022, 1-13.
33. Feng, F.; Liu, M.; Pan, L.; et al. Biomechanical regulatory factors and therapeutic targets in keloid fibrosis. Front. Pharmacol. 2022, 13, 906212.
34. Stone, R. C.; Pastar, I.; Ojeh, N.; et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell. Tissue. Res. 2016, 365, 495-506.
35. Lee, Y. I.; Shim, J. E.; Kim, J.; et al. WNT5A drives interleukin-6-dependent epithelial–mesenchymal transition via the JAK/STAT pathway in keloid pathogenesis. Burns. Trauma. 2022, 10, tkac023.
36. Ma, X.; Chen, J.; Xu, B.; et al. Keloid-derived keratinocytes acquire a fibroblast-like appearance and an enhanced invasive capacity in a hypoxic microenvironment in vitro. Int. J. Mol. Med. 2015, 35, 1246-56.
37. Shi, Y.; Wang, S.; Yang, R.; et al. ROS promote hypoxia‐induced keratinocyte epithelial‐mesenchymal transition by inducing SOX2 expression and subsequent activation of Wnt/β‐catenin. Oxid. Med. Cell. Longev. 2022, 2022, 1084006.
38. Kim, H. J.; Kim, Y. H. Comprehensive insights into keloid pathogenesis and advanced therapeutic strategies. Int. J. Mol. Sci. 2024, 25, 8776.
39. Zhang, T.; Wang, X. F.; Wang, Z. C.; et al. Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation. Biomed. Pharmacother. 2020, 129, 110287.
40. Zhou, B.; Wang, W.; Wu, X.; et al. Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization. Acta. Pharmacol. Sin. 2020, 41, 1234-45.
41. Mohamad, N. E.; Abd El Raheem, T. A.; Mahmoud, R. H.; Hamed, N. O. Evaluating serum level of thymidylate synthase in post burn keloid patients before and after intralesional injection of 5-fluorouracil. Scars. Burns. Heal. 2022, 8.
42. Wang, X.; Liang, B.; Li, J.; et al. Identification and characterization of four immune-related signatures in keloid. Front. Immunol. 2022, 13, 942446.





